Dr. Kehan Xu is an adjunct professor at City University of Hong Kong. Dr. Xu’s research focuses on marketing-finance interface and portfolio strategy (global long/short equity, bond, & event-driven) of innovative industries. Dr. Xu has published in top scholarly journals such as Journal of the Academy of Marketing Science, Journal of Management Accounting Research, Journal of Management, and Academy of Management Perspectives. Dr. Xu presents cutting-edge research findings based on quantitative models in American Marketing Association annual conferences for topics of product innovation, brand disposal and acquisition, and short-selling. Kehan Xu received his PhD from the Mays Business School at Texas A&M University, and his MBA in investments from the University of Miami. Dr. Xu is the co-founder of Dawnrays Biotech Capital (Asia) Limited, which focuses on innovative monoclonal antibody (mAb) projects and clinical studies.
Pyxis Wealth advisors limited is regulated by the Hong Kong Securities & Futures Commission to carry on Types 1 (Dealing in Securities), Type 4 (Advising on Securities), and Type 9 (Asset Management) regulated activities.
Copyright 2022 © PYXIS WEALTH ADVISORS LIMITED. ALL RIGHTS RESERVED. | Terms of use & Disclaimer | privacy policy